Multi-pass Transmembrane Proteins and Technology Platforms

 

Category: *CDMO

Exhibitor: ACROBIOSYSTEMS CO., LTD.

Booth No: M1033

 

Characteristic

 

In order to develop effective therapeutic targeting these TPs, a full length and biologically relevant form of these proteins needs to be isolated. Particularly, multi-pass TPs are notoriously difficult to purify due to complex structures with multiple hydrophobic transmembrane regions and low expression level in host cells but have become highly sought-after disease target.
ACROBiosystems has specially set up multiple technology platforms to address the structural complexity of multi-pass TPs and meet the needs of different application. ACRO has developed a full range of full-length multi-pass TPs with stabilized structure and high activity including CD20, Claudin18.2, CD133, GPRC5D, CXCR4, CCR5 and CCR8 to facilitate drug development and mechanism studies.

 

Other Products

 

• 

  Key Raw Materials for Cell and Gene Therapy

• 

  Toolbox for ADC Targets: the Magic Bullets

• 

  Star Staining Fluorescent-labeled Products

• 

  Immune Checkpoint Proteins

• 

  GMP Grade Solutions for Cell Therapy

• 

  High-quality Fc Receptor Proteins

• 

  Bispecific antibody targets and services

• 

  FDA DMF Filed Proteins

• 

  Residue Detection kits/

 

 

 

Back